Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 209

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Quarterly Psychedelics Briefing: Q3 2026

Weekly Psychedelic Policy Briefing, September 21, 2026

Health Canada Authorizes Optimi’s Natural Psilocybin Trial as House Bill Targets Botanical Drug Exclusivity

Pα+ Psychedelic Bulletin #232: Q2’26 Psychedelic Lobbying Update; DEA Again Moves to Schedule 5 Tryptamines; Oregon Backpedals Psilocybin Fee Hike

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

Mydecine Submits Pre-Investigational New Drug Briefing Package to the FDA for...

Psychedelic or Not: Of Mice, 5-HT2A Agonists, and Head Shakes

PT289 – Payton Nyquvest – Shifting the Mindset on Pain, Psychedelics,...

Psychedelic Bulletin: MDMA Fast-Tracked in UK; FDA Clears MindMed LSD Trial;...

Red Light Holland’s Partner CCrest Laboratories Approved By Health Canada to...

PT288 – Annie & Michael Mithoefer – Vital Psychedelic Conversations

Numinus Identified as a Licensed Psilocybin Supplier by Health Canada

MDMA-Assisted Psychotherapy for PTSD: Interviewing Dr. Rachel Yehuda

Nova Mentis and KGK Science Form Tactical Partnership

Numinus Wellness Inc. Graduates to the OTCQX Best Market

Load more

EDITOR PICKS

Quarterly Psychedelics Briefing: Q3 2026

Weekly Psychedelic Policy Briefing, September 21, 2026

Health Canada Authorizes Optimi’s Natural Psilocybin Trial as House Bill Targets...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©